# TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria

> **NCT07268131** · NA · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **COMBINATION_PRODUCT:** TACE+QL1706

## Key facts

- **NCT ID:** NCT07268131
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-20
- **Primary completion:** 2026-10-31
- **Final completion:** 2029-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07268131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07268131, "TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07268131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*